Vimpat is a drug used for the elimination of the epilepsy symptoms – seizures. Patients prone to epileptic seizures may buy Vimpat without prescription and use it as an extra treatment for epilepsy symptoms.
Vimpat has an anticonvulsant activity that is achieved through the active ingredient Lacosamide. This amino acid has a unique spectrum of action that differs from other anti-epileptic drugs. Vimpat helps reduce hyperexcitability of neurons that have an irritating effect on the epileptic brain center.
Vimpat assists to the sequential deactivation of the sodium channels. This leads to a gradual suppression of epileptic discharges in the brain, without affecting the normal transmission of excitation in the brain.
Vimpat is qualitatively different from the sodium channel blockers, which completely block the transmission of nerve impulses to the brain and are often used to treat epilepsy. Thus, Vimpat is able to delay increased seizure activity.
Vimpat is rapidly and well absorbed after the oral administration. The drug has a 100% bioavailability, while the maximum plasma concentration is reached in about 0.5-4 hours. The half-life of Vimpat is about 13 hours, and the maximum therapeutic effect is reached on the third day of the drug use.
Dosage forms, in which may buy Vimpat without prescription:
- tablets of 50 mg, 100 mg, 150 mg, 200 mg;
- oral solution of 10 mg/ml, 15 mg/ml;
- injectable solution for infusions 10 mg/ml.
Vimpat tablets must be taken twice a day – in the morning and in the evening. Meals do not affect the bioavailability and extent of the drug absorption. The initial dose is 50 mg twice daily. In a week of treatment with Vimpat, the daily dose may be increased to 200 mg, divided in two intakes.
If the medical professional considers it necessary, the patient may also be prescribed to a single loading Vimpat dose of 200 mg. Doctors prescribe the loading dose, when they deem it necessary to rapidly achieve the steady state plasma concentrations of Vimpat.
Twelve hours after the loading Vimpat dose of 200 mg, the patient may take the maintenance dose of 100 mg. Depending on the efficacy and tolerance, the maintenance dose may be increased to 150 mg twice a day approximately in the third week of Vimpat administration. The maximum daily dose of Vimpat should not exceed 400 mg.
Recommendations for the use of Vimpat solution practically do not differ from the pills. Yet, the injectable form of the drug should be used in case of the patient’s inability to take pills, for example, if he has difficulties with swallowing.
Intravenous Vimpat injections are administered in the same dosages, as the oral dosage forms of the drug. The duration of a single intravenous administration of Vimpat may last 0.5-1 hour. The transition from oral to intravenous Vimpat administration or vice versa may be carried out at once, without dose titration.
Vimpat discontinuation should be performed by a gradual dosage reduction. The dose should be reduced by 200 mg each week. Sharp cessation of Vimpat use may cause adverse reactions, such as seizures, loss of consciousness, or headaches.
The benefits of Vimpat:
- minimal drug interactions;
- possibility of a safe use in the elderly;
- presence of three pharmaceutical forms – tablets, solution and injections – provides flexibility in the drug administration;
- is not metabolized in the liver, does not affect liver enzymes and therefore has a virtually ideal pharmacokinetic profile.
The anticonvulsant Vimpat activity is enhanced in a combined therapy with such anticonvulsants, as Levetiracetam, Carbamazepine, Phenytoin, Lamotrigine, Topiramate and Gabapentin.
Like any other drug, Vimpat may lead to side effects at times. These may include hypersensitivity reactions, insomnia and dizziness. Yet, the frequency and severity of these adverse reactions is small, most side effects are dose-dependent, occur at the stage of dose titration, and may be eliminated by a slower increase of Vimpat dose.
Vimpat was the first Lacosamide-based drug. This antiepileptic drug is an original development of the German pharmaceutical company Schwarz Pharma. Clinical trials, which confirmed the anticonvulsant activity of Lacosamide, were conducted in 2000.
However, in 2007, Schwarz Pharma has become part of the Belgian company UCB. Namely UCB released Lacosamide for the first time on the pharmaceutical market under the brand name Vimpat. This happened in 2008.
Since October 29, 2008, Vimpat tablet were available in the USA. Solution for oral administration and the injectable form of Vimpat went on sale two years later, in 2010.
Today, you may buy this anticonvulsant in many online pharmacies. However, before you buy Vimpat online without prescription, we recommend you to visit the official website of the drug manufacturer.
Registered users have the opportunity to buy a month’s supply of Vimpat without prescription for just $ 20. USA residents may get a special savings card, which provides discounts for all Vimpat purchases.